Home » Topics » BioWorld Science

BioWorld Science
RSS

CRADA to develop stem cell technology for cardiovascular disease treatment

May 25, 2004

Onco TCS NDA accepted for review

May 25, 2004

Enrollment commences in phase III Altropane trial

May 25, 2004

Ziconotide could be safe and effective in malignant and nonmalignant pain

May 25, 2004

Duloxetine may be safe and effective for diabetic neuropathic pain

May 25, 2004

Enzo Biochem to begin phase I trial of EGS-21

May 25, 2004

Positive data reported from phase IIIb Xyrem study

May 25, 2004

Phase 2 Discovery receives positive results from phase II trial with PD-6735

May 25, 2004

Zimycan receives approval in Belgium for treatment of diaper dermatitis

May 25, 2004

Avelox approved for treatment of CAP caused by multidrug resistant S. pneumoniae

May 25, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 4, 2026.
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.
EQ-504 is AhR agonist for ulcerative colitis, related disorders
BioWorld Science
Activating the aryl hydrocarbon receptor (AhR) in immune cells enhances anti-inflammatory pathways and limits pathogenic immune responses. Equillium Inc. has...
Quintuple GLP-1–GIP–PPAR agonist for obesity and diabetes control
BioWorld
A new molecule combines the action of two incretins, GLP-1 and GIP, hormones that regulate glucose and appetite, with lanifibranor, a triple agonist of peroxisome...